{"transactions":[{"id":4634910,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35634,"kind":"person","name":"Jin David","position":1,"cik":"0001930732","reported_name":"Jin David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.001","published_at":"2026-10-02T00:30:17.000Z","date":"2026-10-01","kind":"grant","planned":false,"acquired":true,"shares":1190,"price":1.819,"value":2164.61,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting an acquisition of shares under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 1,230,000 shares underlying deferred restricted stock units and 400,000 shares underlying restricted stock units."}],"balance_after":1652761,"source":{"system":"sec-edgar","filing":"0001930732-26-000006","document":"form4-10012026_041005.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000193073226000006/form4-10012026_041005.xml","form_type":"4"}},{"id":727537,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35634,"kind":"person","name":"Jin David","position":1,"cik":"0001930732","reported_name":"Jin David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.001","published_at":"2026-06-25T01:50:03.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of 400,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in four equal annual installments, with the first installment vesting on January 5, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Vested restricted stock units will be settled in shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 1,230,000 shares underlying previously granted deferred restricted stock units."}],"balance_after":1651571,"source":{"system":"sec-edgar","filing":"0001930732-26-000003","document":"form4-06252026_010600.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000193073226000003/form4-06252026_010600.xml","form_type":"4"}},{"id":822762,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35634,"kind":"person","name":"Jin David","position":1,"cik":"0001930732","reported_name":"Jin David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.001","published_at":"2026-04-01T20:05:13.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":2967,"price":2.176,"value":6456.192,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting an acquisition of shares under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 1,230,000 shares underlying deferred restricted stock units."}],"balance_after":1251571,"source":{"system":"sec-edgar","filing":"0001930732-26-000002","document":"form4-04012026_040401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000193073226000002/form4-04012026_040401.xml","form_type":"4"}},{"id":832764,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CEO & CHAIRMAN"}}],"security":"Common stock, par value $0.001","published_at":"2026-03-20T20:05:13.000Z","date":"2026-03-18","kind":"grant","planned":false,"acquired":true,"shares":475424,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 475,424 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on March 18, 2026."}],"balance_after":4586841,"source":{"system":"sec-edgar","filing":"0000941841-26-000002","document":"form4-03202026_040304.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000094184126000002/form4-03202026_040304.xml","form_type":"4"}},{"id":832687,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":56902,"kind":"person","name":"WEISS MICHAEL S","position":1,"cik":"0001038977","reported_name":"WEISS MICHAEL S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice Chairman"}}],"security":"common stock, par value $0.001","published_at":"2026-03-20T16:05:10.000Z","date":"2026-03-18","kind":"grant","planned":false,"acquired":true,"shares":475424,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 475,424 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on March 18, 2026."}],"balance_after":2276562,"source":{"system":"sec-edgar","filing":"0001038977-26-000002","document":"form4-03202026_040301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1038977/000103897726000002/form4-03202026_040301.xml","form_type":"4"}},{"id":951064,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70289,"kind":"person","name":"Harvey Jimmie","position":1,"cik":"0001529687","reported_name":"Harvey Jimmie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock, par value $0.001","published_at":"2026-01-05T21:30:43.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":27322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service.  The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions.  Vested deferred shares will be delivered to the Reporting Person on the January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 143,365 shares underlying deferred restricted stock units."}],"balance_after":146704,"source":{"system":"sec-edgar","filing":"0001529687-26-000002","document":"form4-01052026_040117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000152968726000002/form4-01052026_040117.xml","form_type":"4"}},{"id":951063,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70288,"kind":"person","name":"Lorenz Kevin","position":1,"cik":"0001772558","reported_name":"Lorenz Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock, par value $0.001","published_at":"2026-01-05T21:30:37.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":27322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service."}],"balance_after":101009,"source":{"system":"sec-edgar","filing":"0001772558-26-000002","document":"form4-01052026_040115.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000177255826000002/form4-01052026_040115.xml","form_type":"4"}},{"id":951061,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2026-01-05T21:30:29.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":27322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service.  The Reporting Person elected to defer 25% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions.  Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 52,507 shares underlying deferred restricted stock units."}],"balance_after":115747,"source":{"system":"sec-edgar","filing":"0001294517-26-000002","document":"form4-01052026_040113.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000129451726000002/form4-01052026_040113.xml","form_type":"4"}},{"id":951396,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70314,"kind":"person","name":"Klein Dov","position":1,"cik":"0001647971","reported_name":"Klein Dov","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock, par value $0.001","published_at":"2026-01-05T16:30:44.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":27322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service.  The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions.  Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 102,668 shares underlying deferred restricted stock units."}],"balance_after":130105,"source":{"system":"sec-edgar","filing":"0001647971-26-000002","document":"form4-01052026_040119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647971/000164797126000002/form4-01052026_040119.xml","form_type":"4"}},{"id":952505,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock, par value $0.001","published_at":"2026-01-05T16:30:26.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":27322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service.  The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions.  Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 76,705 shares underlying deferred restricted stock units."}],"balance_after":192397,"source":{"system":"sec-edgar","filing":"0001172659-26-000002","document":"form4-01052026_040120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000117265926000002/form4-01052026_040120.xml","form_type":"4"}},{"id":1027043,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35634,"kind":"person","name":"Jin David","position":1,"cik":"0001930732","reported_name":"Jin David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.001","published_at":"2025-10-02T20:30:13.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":2711,"price":1.309,"value":3548.699,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting an acquisition of shares under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 1,230,000 shares underlying deferred restricted stock units."}],"balance_after":1248604,"source":{"system":"sec-edgar","filing":"0001930732-25-000004","document":"form4-10022025_041001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000193073225000004/form4-10022025_041001.xml","form_type":"4"}},{"id":1186338,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35634,"kind":"person","name":"Jin David","position":1,"cik":"0001930732","reported_name":"Jin David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.001","published_at":"2025-04-01T20:20:16.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":1.2155,"value":6077.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting an acquisition of shares under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 1,230,000 shares underlying deferred restricted stock units."}],"balance_after":1245893,"source":{"system":"sec-edgar","filing":"0001415889-25-009369","document":"form4-04012025_080413.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000141588925009369/form4-04012025_080413.xml","form_type":"4"}},{"id":1314440,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":49473,"kind":"person","name":"Lu Lucy","position":1,"cik":"0001542419","reported_name":"Lu Lucy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock, par value $0.001","published_at":"2025-01-03T21:20:13.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":49383,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 49,383 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2026, 2027, and 2028, subject to continued service.  The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions.  Vested shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 58,047 shares underlying deferred restricted stock units."}],"balance_after":61273,"source":{"system":"sec-edgar","filing":"0001415889-25-000428","document":"form4-01032025_040107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000141588925000428/form4-01032025_040107.xml","form_type":"4"}},{"id":1314439,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70289,"kind":"person","name":"Harvey Jimmie","position":1,"cik":"0001529687","reported_name":"Harvey Jimmie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock, par value $0.001","published_at":"2025-01-03T21:20:11.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":49383,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 49,383 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2026, 2027, and 2028, subject to continued service.  The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions.  Vested deferred shares will be delivered to the Reporting Person on the January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 116,043 shares underlying deferred restricted stock units."}],"balance_after":119382,"source":{"system":"sec-edgar","filing":"0001415889-25-000427","document":"form4-01032025_040105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000141588925000427/form4-01032025_040105.xml","form_type":"4"}},{"id":1314437,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70288,"kind":"person","name":"Lorenz Kevin","position":1,"cik":"0001772558","reported_name":"Lorenz Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock, par value $0.001","published_at":"2025-01-03T21:20:09.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":49383,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 49,383 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2026, 2027, and 2028, subject to continued service."}],"balance_after":73687,"source":{"system":"sec-edgar","filing":"0001415889-25-000426","document":"form4-01032025_040103.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000141588925000426/form4-01032025_040103.xml","form_type":"4"}},{"id":1314438,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2025-01-03T21:20:05.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":49383,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 49,383 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2026, 2027, and 2028, subject to continued service.  The reporting person elected to defer 25% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions.  Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 45,676 shares underlying deferred restricted stock units."}],"balance_after":88425,"source":{"system":"sec-edgar","filing":"0001415889-25-000425","document":"form4-01032025_040101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000141588925000425/form4-01032025_040101.xml","form_type":"4"}},{"id":1316643,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CEO & CHAIRMAN"}}],"security":"Common stock, par value $0.001","published_at":"2025-01-03T21:15:06.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":454153,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 454,153 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on January 1, 2025."}],"balance_after":4111417,"source":{"system":"sec-edgar","filing":"0001415889-25-000400","document":"form4-01032025_040103.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000141588925000400/form4-01032025_040103.xml","form_type":"4"}},{"id":1315723,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock, par value $0.001","published_at":"2025-01-03T16:28:30.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":49383,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 49,383 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2026, 2027, and 2028, subject to continued service.  The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions.  Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 49,383 shares underlying deferred restricted stock units."}],"balance_after":165075,"source":{"system":"sec-edgar","filing":"0001415889-25-000444","document":"form4-01032025_090127.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000141588925000444/form4-01032025_090127.xml","form_type":"4"}},{"id":1314723,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70314,"kind":"person","name":"Klein Dov","position":1,"cik":"0001647971","reported_name":"Klein Dov","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock, par value $0.001","published_at":"2025-01-03T16:20:17.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":49383,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 49,383 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2026, 2027, and 2028, subject to continued service.  The reporting person elected to defer 50% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions.  Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 75,346 shares underlying deferred restricted stock units."}],"balance_after":102783,"source":{"system":"sec-edgar","filing":"0001415889-25-000429","document":"form4-01032025_040109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647971/000141588925000429/form4-01032025_040109.xml","form_type":"4"}},{"id":1316026,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":56902,"kind":"person","name":"WEISS MICHAEL S","position":1,"cik":"0001038977","reported_name":"WEISS MICHAEL S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice Chairman"}}],"security":"common stock, par value $0.001","published_at":"2025-01-03T16:15:10.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":454153,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 454,153 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on January 1, 2025."}],"balance_after":1801138,"source":{"system":"sec-edgar","filing":"0001415889-25-000402","document":"form4-01032025_040105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1038977/000141588925000402/form4-01032025_040105.xml","form_type":"4"}},{"id":1322758,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35634,"kind":"person","name":"Jin David","position":1,"cik":"0001930732","reported_name":"Jin David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.001","published_at":"2024-12-23T21:30:05.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of 1,000,000 restricted stock units which will vest in 16 equal quarterly installments beginning after December 20, 2024. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and the consummation of a Corporate Transaction (as defined in the Fortress Biotech, Inc. 2013 Stock Incentive Plan); the amount will be distributed in the form of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 1,230,000 shares underlying deferred restricted stock units."}],"balance_after":1240893,"source":{"system":"sec-edgar","filing":"0001415889-24-030071","document":"form4-12232024_041201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000141588924030071/form4-12232024_041201.xml","form_type":"4"}},{"id":1396662,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35634,"kind":"person","name":"Jin David","position":1,"cik":"0001930732","reported_name":"Jin David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.001","published_at":"2024-10-01T20:15:07.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":2625,"price":1.2283,"value":3224.2875,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting an acquisition of shares under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 230,000 shares underlying deferred restricted stock units."}],"balance_after":240893,"source":{"system":"sec-edgar","filing":"0001415889-24-024183","document":"form4-10012024_041004.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000141588924024183/form4-10012024_041004.xml","form_type":"4"}},{"id":1399726,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CEO & CHAIRMAN"}}],"security":"Warrants to Purchase Common Stock","published_at":"2024-09-25T20:45:04.000Z","date":"2024-09-23","kind":"purchase","planned":false,"acquired":true,"shares":763359,"price":0.125,"value":95419.875,"ownership":{"direct":true},"balance_after":763359,"derivative":{"exercise_price":1.84,"exercise_date":"2025-03-23","expiration_date":"2030-03-23","underlying":"Common Stock","underlying_shares":763359},"source":{"system":"sec-edgar","filing":"0001415889-24-023957","document":"form4-09252024_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/941841/000141588924023957/form4-09252024_040901.xml","form_type":"4"}},{"id":1399725,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CEO & CHAIRMAN"}}],"security":"Common stock, par value $0.001","published_at":"2024-09-25T20:45:04.000Z","date":"2024-09-23","kind":"purchase","planned":false,"acquired":true,"shares":763359,"price":1.84,"value":1404580.56,"ownership":{"direct":true},"balance_after":3657264,"source":{"system":"sec-edgar","filing":"0001415889-24-023957","document":"form4-09252024_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000141588924023957/form4-09252024_040901.xml","form_type":"4"}},{"id":1454870,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO & Chairman"}}],"security":"SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK","published_at":"2024-07-15T20:05:14.000Z","date":"2024-07-11","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":7.4835,"value":37417.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on July 11, 2024 was $7.35 to $7.49. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":127500,"source":{"system":"sec-edgar","filing":"0001104659-24-079855","document":"tm2419471-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465924079855/tm2419471-1_4seq1.xml","form_type":"4"}},{"id":1455240,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35634,"kind":"person","name":"Jin David","position":1,"cik":"0001930732","reported_name":"Jin David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK","published_at":"2024-07-12T12:42:21.000Z","date":"2024-07-10","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":7.5,"value":3750.0,"ownership":{"direct":true},"balance_after":500,"source":{"system":"sec-edgar","filing":"0001104659-24-079409","document":"tm2419335-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924079409/tm2419335-1_4seq1.xml","form_type":"4"}},{"id":1456482,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO & Chairman"}}],"security":"SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK","published_at":"2024-07-11T12:00:09.000Z","date":"2024-07-09","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":7.3942,"value":36971.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on July 9, 2024 was $7.25 to $7.48. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":122500,"source":{"system":"sec-edgar","filing":"0001104659-24-079100","document":"tm2419219-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465924079100/tm2419219-1_4seq1.xml","form_type":"4"}},{"id":1457109,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO & Chairman"}}],"security":"SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK","published_at":"2024-07-10T12:30:11.000Z","date":"2024-07-08","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":7.3529,"value":36764.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on July 8, 2024 was $7.29 to $7.47. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":117500,"source":{"system":"sec-edgar","filing":"0001104659-24-078786","document":"tm2419164-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465924078786/tm2419164-1_4seq1.xml","form_type":"4"}},{"id":1466494,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO & Chairman"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2024-07-01T12:40:16.000Z","date":"2024-06-28","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":1.6362,"value":32724.0,"ownership":{"direct":true},"balance_after":2893905,"source":{"system":"sec-edgar","filing":"0001104659-24-076591","document":"tm2418613-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465924076591/tm2418613-1_4seq1.xml","form_type":"4"}},{"id":1509607,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO & Chairman"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2024-05-20T21:00:38.000Z","date":"2024-05-16","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":1.7589,"value":17589.0,"ownership":{"direct":true},"balance_after":2873905,"source":{"system":"sec-edgar","filing":"0001104659-24-063455","document":"tm2415000-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465924063455/tm2415000-2_4seq1.xml","form_type":"4"}},{"id":1508978,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70314,"kind":"person","name":"Klein Dov","position":1,"cik":"0001647971","reported_name":"Klein Dov","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2024-05-20T16:56:41.000Z","date":"2024-05-20","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":1.89,"value":18900.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Total holdings include 50,655 shares underlying deferred restricted stock and restricted stock units."}],"balance_after":53400,"source":{"system":"sec-edgar","filing":"0001104659-24-063451","document":"tm2415000-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647971/000110465924063451/tm2415000-1_4seq1.xml","form_type":"4"}},{"id":1553312,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35634,"kind":"person","name":"Jin David","position":1,"cik":"0001930732","reported_name":"Jin David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2024-04-02T20:06:15.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":2352,"price":1.7,"value":3998.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person is voluntarily reporting an acquisition of shares under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 230,000 shares underlying deferred restricted stock units."}],"balance_after":238268,"source":{"system":"sec-edgar","filing":"0001104659-24-042504","document":"tm2410608-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924042504/tm2410608-1_4seq1.xml","form_type":"4"}},{"id":1683214,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO & Chairman"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2024-01-09T13:15:16.000Z","date":"2024-01-05","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":2.3754,"value":118770.0,"ownership":{"direct":true},"balance_after":2863905,"source":{"system":"sec-edgar","filing":"0001104659-24-002464","document":"tm242385-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465924002464/tm242385-1_4seq1.xml","form_type":"4"}},{"id":1691995,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":49473,"kind":"person","name":"Lu Lucy","position":1,"cik":"0001542419","reported_name":"Lu Lucy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2024-01-03T21:55:23.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split."},{"field":"shares","element":"transactionShares","label":"F2","text":"One-third of the shares will vest on each of January 1, 2025, 2026, and 2027, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Total holdings include 8,664 shares underlying deferred restricted stock units."}],"balance_after":11890,"source":{"system":"sec-edgar","filing":"0001104659-24-000915","document":"tm241755-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924000915/tm241755-9_4seq1.xml","form_type":"4"}},{"id":1691994,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70288,"kind":"person","name":"Lorenz Kevin","position":1,"cik":"0001772558","reported_name":"Lorenz Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2024-01-03T21:54:05.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split."},{"field":"shares","element":"transactionShares","label":"F2","text":"One-third of the shares will vest on each of January 1, 2025, 2026, and 2027, subject to continued service."}],"balance_after":24304,"source":{"system":"sec-edgar","filing":"0001104659-24-000913","document":"tm241755-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924000913/tm241755-8_4seq1.xml","form_type":"4"}},{"id":1691993,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2024-01-03T21:50:39.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split."},{"field":"shares","element":"transactionShares","label":"F2","text":"One-third of the shares will vest on each of January 1, 2025, 2026, and 2027, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Total holdings include 33,330 shares underlying deferred restricted stock units."}],"balance_after":39042,"source":{"system":"sec-edgar","filing":"0001104659-24-000905","document":"tm241755-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924000905/tm241755-5_4seq1.xml","form_type":"4"}},{"id":1691992,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70289,"kind":"person","name":"Harvey Jimmie","position":1,"cik":"0001529687","reported_name":"Harvey Jimmie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2024-01-03T21:49:12.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":6666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split."},{"field":"shares","element":"transactionShares","label":"F2","text":"One-third of the shares will vest on each of January 1, 2025, 2026, and 2027, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Total holdings include 66,660 shares underlying deferred restricted stock units."}],"balance_after":69999,"source":{"system":"sec-edgar","filing":"0001104659-24-000901","document":"tm241755-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924000901/tm241755-4_4seq1.xml","form_type":"4"}},{"id":1691991,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":39449,"kind":"person","name":"Rowinsky Eric K","position":1,"cik":"0001318886","reported_name":"Rowinsky Eric K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2024-01-03T21:47:48.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":6666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split."},{"field":"shares","element":"transactionShares","label":"F2","text":"One-third of the shares will vest on each of January 1, 2025, 2026, and 2027, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Total holdings include 19,998 shares underlying deferred restricted stock units."}],"balance_after":68797,"source":{"system":"sec-edgar","filing":"0001104659-24-000899","document":"tm241755-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924000899/tm241755-11_4seq1.xml","form_type":"4"}},{"id":1694427,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO & Chairman"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2024-01-03T21:46:48.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":216465,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 216,465 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on January 1, 2024."}],"balance_after":2813905,"source":{"system":"sec-edgar","filing":"0001104659-24-000898","document":"tm241755-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465924000898/tm241755-10_4seq1.xml","form_type":"4"}},{"id":1693506,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2024-01-03T16:52:27.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":6666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split."},{"field":"shares","element":"transactionShares","label":"F2","text":"One-third of the shares will vest on each of January 1, 2025, 2026, and 2027, subject to continued service."}],"balance_after":115692,"source":{"system":"sec-edgar","filing":"0001104659-24-000912","document":"tm241755-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000110465924000912/tm241755-7_4seq1.xml","form_type":"4"}},{"id":1692426,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70314,"kind":"person","name":"Klein Dov","position":1,"cik":"0001647971","reported_name":"Klein Dov","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2024-01-03T16:51:06.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":6666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split."},{"field":"shares","element":"transactionShares","label":"F2","text":"One-third of the shares will vest on each of January 1, 2025, 2026, and 2027, subject to continued service. The reporting person elected to defer 5,332 of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Total holdings include 50,655 shares underlying deferred restricted stock and restricted stock units."}],"balance_after":63400,"source":{"system":"sec-edgar","filing":"0001104659-24-000908","document":"tm241755-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647971/000110465924000908/tm241755-6_4seq1.xml","form_type":"4"}},{"id":1693780,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":56902,"kind":"person","name":"WEISS MICHAEL S","position":1,"cik":"0001038977","reported_name":"WEISS MICHAEL S","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2024-01-03T16:48:36.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":216465,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 216,465 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on January 1, 2024."}],"balance_after":1346985,"source":{"system":"sec-edgar","filing":"0001104659-24-000900","document":"tm241755-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1038977/000110465924000900/tm241755-12_4seq1.xml","form_type":"4"}},{"id":1700734,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35634,"kind":"person","name":"Jin David","position":1,"cik":"0001930732","reported_name":"Jin David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-12-22T21:05:23.000Z","date":"2023-12-20","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents an award of 140,000 restricted stock units which will vest in 16 equal quarterly installments after the grant date, December 20, 2023. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and the consummation of a Corporate Transaction (as defined in the Fortress Biotech, Inc. 2013 Stock Incentive Plan); the amount will be distributed in the form of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Total holdings include 230,000 shares underlying deferred restricted stock units."}],"balance_after":235916,"source":{"system":"sec-edgar","filing":"0001104659-23-128788","document":"tm2333573-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923128788/tm2333573-1_4seq1.xml","form_type":"4"}},{"id":1739746,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO & Chairman"}}],"security":"Warrants to purchase Common Stock","published_at":"2023-11-16T22:50:28.000Z","date":"2023-11-14","kind":"purchase","planned":false,"acquired":true,"shares":1567515,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of common stock and warrants to purchase common stock reflect on this Form 4 were purchased as units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at a price per unit of $1.70."}],"balance_after":1567515,"derivative":{"exercise_price":1.7,"exercise_date":"2023-11-14","expiration_date":"2028-11-14","underlying":"Common Stock","underlying_shares":1567515},"source":{"system":"sec-edgar","filing":"0001104659-23-119188","document":"tm2330934-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465923119188/tm2330934-2_4seq1.xml","form_type":"4"}},{"id":1739745,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO & Chairman"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-11-16T22:50:28.000Z","date":"2023-11-14","kind":"purchase","planned":false,"acquired":true,"shares":1567515,"price":1.7,"value":2664775.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of common stock and warrants to purchase common stock reflect on this Form 4 were purchased as units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at a price per unit of $1.70."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split."}],"balance_after":2597440,"source":{"system":"sec-edgar","filing":"0001104659-23-119188","document":"tm2330934-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465923119188/tm2330934-2_4seq1.xml","form_type":"4"}},{"id":1739520,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":56902,"kind":"person","name":"WEISS MICHAEL S","position":1,"cik":"0001038977","reported_name":"WEISS MICHAEL S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Warrants to purchase Common Stock","published_at":"2023-11-16T17:46:56.000Z","date":"2023-11-14","kind":"purchase","planned":false,"acquired":true,"shares":147058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of common stock and warrants to purchase common stock reflect on this Form 4 were purchased as units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at a price per unit of $1.70."}],"balance_after":147058,"derivative":{"exercise_price":1.7,"exercise_date":"2023-11-14","expiration_date":"2028-11-14","underlying":"Common Stock","underlying_shares":147058},"source":{"system":"sec-edgar","filing":"0001104659-23-119186","document":"tm2330934-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1038977/000110465923119186/tm2330934-1_4seq1.xml","form_type":"4"}},{"id":1739519,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":56902,"kind":"person","name":"WEISS MICHAEL S","position":1,"cik":"0001038977","reported_name":"WEISS MICHAEL S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-11-16T17:46:56.000Z","date":"2023-11-14","kind":"purchase","planned":false,"acquired":true,"shares":147058,"price":1.7,"value":249998.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of common stock and warrants to purchase common stock reflect on this Form 4 were purchased as units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at a price per unit of $1.70."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split."}],"balance_after":1130520,"source":{"system":"sec-edgar","filing":"0001104659-23-119186","document":"tm2330934-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1038977/000110465923119186/tm2330934-1_4seq1.xml","form_type":"4"}},{"id":1772845,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO & Chairman"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-09-27T12:20:13.000Z","date":"2023-09-26","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":0.2833,"value":28330.0,"ownership":{"direct":true},"balance_after":15449091,"source":{"system":"sec-edgar","filing":"0001104659-23-104099","document":"tm2327003-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465923104099/tm2327003-1_4.xml","form_type":"4"}},{"id":1801118,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO & Chairman"}}],"security":"SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK","published_at":"2023-08-21T12:30:35.000Z","date":"2023-08-18","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":9.34,"value":93400.0,"ownership":{"direct":true},"balance_after":112500,"source":{"system":"sec-edgar","filing":"0001104659-23-093700","document":"tm2324200-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465923093700/tm2324200-1_4seq1.xml","form_type":"4"}},{"id":1801117,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO & Chairman"}}],"security":"SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK","published_at":"2023-08-21T12:30:35.000Z","date":"2023-08-17","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":11.75,"value":117500.0,"ownership":{"direct":true},"balance_after":102500,"source":{"system":"sec-edgar","filing":"0001104659-23-093700","document":"tm2324200-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465923093700/tm2324200-1_4seq1.xml","form_type":"4"}},{"id":2016126,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":39449,"kind":"person","name":"Rowinsky Eric K","position":1,"cik":"0001318886","reported_name":"Rowinsky Eric K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-02-14T21:11:04.000Z","date":"2023-02-10","kind":"purchase","acquired":true,"shares":11976,"price":0.835,"value":9999.96,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The total holdings include 200,000 shares of deferred restricted stock."}],"balance_after":931976,"source":{"system":"sec-edgar","filing":"0001104659-23-021625","document":"tm236803-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923021625/tm236803-5_4seq1.xml","form_type":"4"}},{"id":2017624,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO & Chairman"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-02-14T21:10:16.000Z","date":"2023-02-10","kind":"purchase","acquired":true,"shares":2395209,"price":0.835,"value":1999999.515,"ownership":{"direct":true},"balance_after":15349091,"source":{"system":"sec-edgar","filing":"0001104659-23-021617","document":"tm236803-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465923021617/tm236803-4_4seq1.xml","form_type":"4"}},{"id":2016125,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":49473,"kind":"person","name":"Lu Lucy","position":1,"cik":"0001542419","reported_name":"Lu Lucy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-02-14T21:09:02.000Z","date":"2023-02-10","kind":"purchase","acquired":true,"shares":11976,"price":0.835,"value":9999.96,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The total holdings include 50,000 shares underlying deferred restricted stock units."}],"balance_after":133379,"source":{"system":"sec-edgar","filing":"0001104659-23-021614","document":"tm236803-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923021614/tm236803-3_4seq1.xml","form_type":"4"}},{"id":2016124,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35634,"kind":"person","name":"Jin David","position":1,"cik":"0001930732","reported_name":"Jin David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-02-14T21:06:15.000Z","date":"2023-02-10","kind":"purchase","acquired":true,"shares":35928,"price":0.835,"value":29999.88,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The total holdings include 1,350,000 shares underlying deferred restricted stock units."}],"balance_after":1438757,"source":{"system":"sec-edgar","filing":"0001104659-23-021541","document":"tm236803-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923021541/tm236803-1_4seq1.xml","form_type":"4"}},{"id":2017227,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":56902,"kind":"person","name":"WEISS MICHAEL S","position":1,"cik":"0001038977","reported_name":"WEISS MICHAEL S","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-02-14T16:12:24.000Z","date":"2023-02-10","kind":"purchase","acquired":true,"shares":1197604,"price":0.835,"value":999999.34,"ownership":{"direct":true},"balance_after":14752034,"source":{"system":"sec-edgar","filing":"0001104659-23-021628","document":"tm236803-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1038977/000110465923021628/tm236803-6_4seq1.xml","form_type":"4"}},{"id":2017033,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-02-14T16:07:57.000Z","date":"2023-02-10","kind":"purchase","acquired":true,"shares":299401,"price":0.835,"value":249999.835,"ownership":{"direct":true},"balance_after":1635401,"source":{"system":"sec-edgar","filing":"0001104659-23-021607","document":"tm236803-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000110465923021607/tm236803-2_4seq1.xml","form_type":"4"}},{"id":2070002,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO & Chairman"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-01-05T02:28:22.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":1219294,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The Reporting Person was granted 1,219,294 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on January 1, 2023."}],"balance_after":12953882,"source":{"system":"sec-edgar","filing":"0001104659-23-001103","document":"tm231728-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465923001103/tm231728-9_4seq1.xml","form_type":"4"}},{"id":2070001,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO & Chairman"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-01-05T02:28:22.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":4264,"price":0.73,"value":3112.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":11734588,"source":{"system":"sec-edgar","filing":"0001104659-23-001103","document":"tm231728-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465923001103/tm231728-9_4seq1.xml","form_type":"4"}},{"id":2067009,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":49473,"kind":"person","name":"Lu Lucy","position":1,"cik":"0001542419","reported_name":"Lu Lucy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-01-05T02:27:43.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of January1, 2024, 2025 and 2026, subject to continued service. The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the reporting person's termination of service, or earlier upon her death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 50,000 shares underlying deferred restricted stock units."}],"balance_after":121403,"source":{"system":"sec-edgar","filing":"0001104659-23-001102","document":"tm231728-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923001102/tm231728-8_4seq1.xml","form_type":"4"}},{"id":2067008,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":39449,"kind":"person","name":"Rowinsky Eric K","position":1,"cik":"0001318886","reported_name":"Rowinsky Eric K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-01-05T02:26:27.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of January1, 2024, 2025 and 2026, subject to continued service. The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 200,000 shares of deferred restricted stock."}],"balance_after":920000,"source":{"system":"sec-edgar","filing":"0001104659-23-001100","document":"tm231728-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923001100/tm231728-6_4seq1.xml","form_type":"4"}},{"id":2067007,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70288,"kind":"person","name":"Lorenz Kevin","position":1,"cik":"0001772558","reported_name":"Lorenz Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-01-05T02:25:59.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of January1, 2024, 2025 and 2026, subject to continued service."}],"balance_after":314572,"source":{"system":"sec-edgar","filing":"0001104659-23-001099","document":"tm231728-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923001099/tm231728-5_4seq1.xml","form_type":"4"}},{"id":2067006,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-01-05T02:24:18.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of January1, 2024, 2025 and 2026, subject to continued service. The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 450,000 shares underlying deferred restricted stock units."}],"balance_after":535636,"source":{"system":"sec-edgar","filing":"0001104659-23-001095","document":"tm231728-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923001095/tm231728-2_4seq1.xml","form_type":"4"}},{"id":2067005,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70289,"kind":"person","name":"Harvey Jimmie","position":1,"cik":"0001529687","reported_name":"Harvey Jimmie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-01-05T02:23:26.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of January1, 2024, 2025 and 2026, subject to continued service. The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 900,000 shares of deferred restricted stock."}],"balance_after":950000,"source":{"system":"sec-edgar","filing":"0001104659-23-001094","document":"tm231728-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923001094/tm231728-1_4seq1.xml","form_type":"4"}},{"id":2069197,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":56902,"kind":"person","name":"WEISS MICHAEL S","position":1,"cik":"0001038977","reported_name":"WEISS MICHAEL S","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-01-04T21:27:11.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":1219294,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 1,219,294 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on January 1, 2023."}],"balance_after":13554430,"source":{"system":"sec-edgar","filing":"0001104659-23-001101","document":"tm231728-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1038977/000110465923001101/tm231728-7_4seq1.xml","form_type":"4"}},{"id":2068789,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-01-04T21:25:28.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of January 1, 2024, 2025 and 2026, subject to continued service."}],"balance_after":1336000,"source":{"system":"sec-edgar","filing":"0001104659-23-001097","document":"tm231728-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000110465923001097/tm231728-4_4seq1.xml","form_type":"4"}},{"id":2067620,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70314,"kind":"person","name":"Klein Dov","position":1,"cik":"0001647971","reported_name":"Klein Dov","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-01-04T21:24:46.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of January1, 2024, 2025 and 2026, subject to continued service. The Reporting Person elected to defer 80,000 of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 560,000 shares of deferred restricted stock and 120,000 shares underlying deferred restricted stock units."}],"balance_after":851015,"source":{"system":"sec-edgar","filing":"0001104659-23-001096","document":"tm231728-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647971/000110465923001096/tm231728-3_4seq1.xml","form_type":"4"}},{"id":2081462,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":49473,"kind":"person","name":"Lu Lucy","position":1,"cik":"0001542419","reported_name":"Lu Lucy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2022-12-19T13:50:26.000Z","date":"2022-12-16","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of December 16, 2023, December 16, 2024 and December 16, 2025."}],"balance_after":71403,"source":{"system":"sec-edgar","filing":"0001104659-22-128075","document":"tm2232939-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465922128075/tm2232939-2_4seq1.xml","form_type":"4"}},{"id":2097014,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CEO & CHAIRMAN"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2022-12-05T12:31:38.000Z","date":"2022-12-01","kind":"purchase","acquired":true,"shares":100000,"price":0.6796,"value":67960.0,"ownership":{"direct":true},"balance_after":11730324,"source":{"system":"sec-edgar","filing":"0001104659-22-124392","document":"tm2231935-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465922124392/tm2231935-1_4seq1.xml","form_type":"4"}},{"id":2099012,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CEO & CHAIRMAN"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2022-12-02T21:18:04.000Z","date":"2022-11-30","kind":"purchase","acquired":true,"shares":5000,"price":0.56,"value":2800.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan (\"ESPP\") during the ESPP offering period. Under the ESPP, 5,000 shares is the maximum amount an individual employee may purchase during an offering period."}],"balance_after":11630324,"source":{"system":"sec-edgar","filing":"0001104659-22-124108","document":"tm2231877-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465922124108/tm2231877-2_4seq1.xml","form_type":"4"}},{"id":2098120,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35634,"kind":"person","name":"Jin David","position":1,"cik":"0001930732","reported_name":"Jin David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2022-12-02T21:14:02.000Z","date":"2022-11-30","kind":"purchase","acquired":true,"shares":5000,"price":0.56,"value":2800.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan (\"ESPP\") during the ESPP offering period. Under the ESPP, 5,000 shares is the maximum amount an individual employee may purchase during an offering period."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 1,350,000 shares underlying restricted stock units."}],"balance_after":1402829,"source":{"system":"sec-edgar","filing":"0001104659-22-124100","document":"tm2231877-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465922124100/tm2231877-1_4seq1.xml","form_type":"4"}},{"id":2130291,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35634,"kind":"person","name":"Jin David","position":1,"cik":"0001930732","reported_name":"Jin David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2022-10-28T21:02:20.000Z","date":"2022-10-26","kind":"grant","acquired":true,"shares":1350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of 1,350,000 restricted stock units which will vest in 48 equal monthly installments after the grant date, October 26, 2022. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and the consummation of a Corporate Transaction (as defined in the Fortress Biotech, Inc. 2013 Stock Incentive Plan); the amount will be distributed in the form of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 1,350,000 shares underlying restricted stock units."}],"balance_after":1397829,"source":{"system":"sec-edgar","filing":"0001104659-22-112522","document":"tm2229153-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465922112522/tm2229153-2_4seq1.xml","form_type":"4"}},{"id":2133176,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CEO & CHAIRMAN"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2022-10-24T12:00:59.000Z","date":"2022-10-21","kind":"purchase","acquired":true,"shares":100000,"price":0.695,"value":69500.0,"ownership":{"direct":true},"balance_after":11625324,"source":{"system":"sec-edgar","filing":"0001104659-22-110780","document":"tm2228777-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465922110780/tm2228777-1_4seq1.xml","form_type":"4"}},{"id":2287836,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":69476,"kind":"person","name":"Hunter Robyn","position":1,"cik":"0001713932","reported_name":"Hunter Robyn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.001","published_at":"2022-04-29T20:25:46.000Z","date":"2021-09-21","kind":"sale","acquired":false,"shares":28292,"price":3.13,"value":88553.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the vesting of 62,500 shares on September 20, 2021, a total of 28,292 of such shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on September 21, 2021, was $3.11 to $3.14. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the 163,877 shares, 34,208 shares are restricted stock units."}],"balance_after":163877,"source":{"system":"sec-edgar","filing":"0001104659-22-053623","document":"tm2213913-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465922053623/tm2213913-9_4seq1.xml","form_type":"4"}},{"id":2287835,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-29T20:22:47.000Z","date":"2022-01-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"One-third of the shares will vest on each of January 1, 2023, 2024, and 2025, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"The total holdings include 400,000 shares underlying deferred restricted stock units."}],"balance_after":485636,"source":{"system":"sec-edgar","filing":"0001104659-22-053616","document":"tm2213913-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465922053616/tm2213913-7_4seq1.xml","form_type":"4"}},{"id":2287834,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-29T20:22:47.000Z","date":"2021-11-16","kind":"other","acquired":true,"shares":230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were issued upon the consummation of Journey Medical Corporation (\"Journey's\") initial public offering as a partial dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey's 8% Cumulative Convertible Class A Preferred Stock"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 350,000 shares underlying deferred restricted stock units."}],"balance_after":435636,"source":{"system":"sec-edgar","filing":"0001104659-22-053616","document":"tm2213913-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465922053616/tm2213913-7_4seq1.xml","form_type":"4"}},{"id":2287833,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-29T20:22:47.000Z","date":"2021-09-30","kind":"other","acquired":true,"shares":406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as a dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey Medical Corporation's 8% Cumulative Convertible Class A Preferred Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 350,000 shares underlying deferred restricted stock units."}],"balance_after":435406,"source":{"system":"sec-edgar","filing":"0001104659-22-053616","document":"tm2213913-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465922053616/tm2213913-7_4seq1.xml","form_type":"4"}},{"id":2288217,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CEO & CHAIRMAN"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2022-04-29T20:22:00.000Z","date":"2022-01-01","kind":"grant","acquired":true,"shares":1102986,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The reporting person was granted 1,102,986 restricted shares pursuant to the issuer's Long-Term Incentive Plan on January 1, 2022."}],"balance_after":11525324,"source":{"system":"sec-edgar","filing":"0001104659-22-053615","document":"tm2213913-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465922053615/tm2213913-6_4seq1.xml","form_type":"4"}},{"id":2288216,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CEO & CHAIRMAN"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2022-04-29T20:22:00.000Z","date":"2021-12-01","kind":"grant","acquired":true,"shares":1250,"price":2.42,"value":3025.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan (\"ESPP\") during the ESPP offering period."}],"balance_after":10422338,"source":{"system":"sec-edgar","filing":"0001104659-22-053615","document":"tm2213913-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465922053615/tm2213913-6_4seq1.xml","form_type":"4"}},{"id":2288215,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CEO & CHAIRMAN"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2022-04-29T20:22:00.000Z","date":"2021-11-16","kind":"other","acquired":true,"shares":4619,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were issued upon the consummation of Journey Medical Corporation (\"Journey's\")  initial public offering as a partial dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey's 8% Cumulative Convertible Class A Preferred Stock."}],"balance_after":10421088,"source":{"system":"sec-edgar","filing":"0001104659-22-053615","document":"tm2213913-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465922053615/tm2213913-6_4seq1.xml","form_type":"4"}},{"id":2288214,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CEO & CHAIRMAN"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2022-04-29T20:22:00.000Z","date":"2021-09-30","kind":"other","acquired":true,"shares":8133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were issued as a dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey Medical Corporation's 8% Cumulative Convertible Class A Preferred Stock."}],"balance_after":10416469,"source":{"system":"sec-edgar","filing":"0001104659-22-053615","document":"tm2213913-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465922053615/tm2213913-6_4seq1.xml","form_type":"4"}},{"id":2288213,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CEO & CHAIRMAN"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2022-04-29T20:22:00.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":1297,"price":2.31,"value":2996.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan (\"ESPP\") during the ESPP offering period."}],"balance_after":10408336,"source":{"system":"sec-edgar","filing":"0001104659-22-053615","document":"tm2213913-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465922053615/tm2213913-6_4seq1.xml","form_type":"4"}},{"id":2287832,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70288,"kind":"person","name":"Lorenz Kevin","position":1,"cik":"0001772558","reported_name":"Lorenz Kevin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2022-04-29T20:20:35.000Z","date":"2022-01-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of January 1, 2023, 2024 and 2025, subject to continued service."}],"balance_after":264572,"source":{"system":"sec-edgar","filing":"0001104659-22-053584","document":"tm2213913-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465922053584/tm2213913-5_4seq1.xml","form_type":"4"}},{"id":2287831,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70289,"kind":"person","name":"Harvey Jimmie","position":1,"cik":"0001529687","reported_name":"Harvey Jimmie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2022-04-29T20:19:00.000Z","date":"2022-01-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of January 1, 2023, 2024 and 2025, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 800,000 shares of deferred restricted stock."}],"balance_after":850000,"source":{"system":"sec-edgar","filing":"0001104659-22-053580","document":"tm2213913-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465922053580/tm2213913-4_4seq1.xml","form_type":"4"}},{"id":2287830,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":39449,"kind":"person","name":"Rowinsky Eric K","position":1,"cik":"0001318886","reported_name":"Rowinsky Eric K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2022-04-29T20:16:50.000Z","date":"2022-01-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each January 1, 2023, 2024 and 2025, subject to continued service."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 100,000 shares of deferred restricted stock."}],"balance_after":820000,"source":{"system":"sec-edgar","filing":"0001104659-22-053572","document":"tm2213913-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465922053572/tm2213913-2_4seq1.xml","form_type":"4"}},{"id":2287905,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70314,"kind":"person","name":"Klein Dov","position":1,"cik":"0001647971","reported_name":"Klein Dov","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2022-04-29T16:26:52.000Z","date":"2022-01-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"One-third of the shares will vest on each of January 1, 2023, 2024 and 2025, subject to continued service. The reporting person elected to defer 80,000 of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"The total holdings include 560,000 shares of deferred restricted stock and 40,000 shares underlying deferred restricted stock units."}],"balance_after":751015,"source":{"system":"sec-edgar","filing":"0001104659-22-053625","document":"tm2213913-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1647971/000110465922053625/tm2213913-10_4seq1.xml","form_type":"4"}},{"id":2287904,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70314,"kind":"person","name":"Klein Dov","position":1,"cik":"0001647971","reported_name":"Klein Dov","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2022-04-29T16:26:52.000Z","date":"2021-12-28","kind":"sale","acquired":false,"shares":5000,"price":2.45,"value":12250.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 480,000 shares of deferred restricted stock and 40,000 shares underlying deferred restricted stock units."}],"balance_after":651015,"source":{"system":"sec-edgar","filing":"0001104659-22-053625","document":"tm2213913-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1647971/000110465922053625/tm2213913-10_4seq1.xml","form_type":"4"}},{"id":2287903,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70314,"kind":"person","name":"Klein Dov","position":1,"cik":"0001647971","reported_name":"Klein Dov","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2022-04-29T16:26:52.000Z","date":"2021-11-16","kind":"other","acquired":true,"shares":230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were issued upon the consummation of Journey Medical Corporation (\"Journey's\") initial public offering as a partial dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey's 8% Cumulative Convertible Class A Preferred Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 480,000 shares of deferred restricted stock and 40,000 shares underlying deferred restricted stock units."}],"balance_after":656015,"source":{"system":"sec-edgar","filing":"0001104659-22-053625","document":"tm2213913-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1647971/000110465922053625/tm2213913-10_4seq1.xml","form_type":"4"}},{"id":2287902,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70314,"kind":"person","name":"Klein Dov","position":1,"cik":"0001647971","reported_name":"Klein Dov","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2022-04-29T16:26:52.000Z","date":"2021-09-30","kind":"other","acquired":true,"shares":480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as a dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey Medical Corporation's 8% Cumulative Convertible Class A Preferred Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 480,000 shares of deferred restricted stock and 40,000 shares underlying deferred restricted stock units."}],"balance_after":655785,"source":{"system":"sec-edgar","filing":"0001104659-22-053625","document":"tm2213913-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1647971/000110465922053625/tm2213913-10_4seq1.xml","form_type":"4"}},{"id":2287901,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70314,"kind":"person","name":"Klein Dov","position":1,"cik":"0001647971","reported_name":"Klein Dov","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2022-04-29T16:26:52.000Z","date":"2021-08-05","kind":"other","acquired":true,"shares":305,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as a dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey Medical Corporation's 8% Cumulative Convertible Class A Preferred Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 480,000 shares of deferred restricted stock and 40,000 shares underlying deferred restricted stock units."}],"balance_after":655305,"source":{"system":"sec-edgar","filing":"0001104659-22-053625","document":"tm2213913-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647971/000110465922053625/tm2213913-10_4seq1.xml","form_type":"4"}},{"id":2288066,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":56902,"kind":"person","name":"WEISS MICHAEL S","position":1,"cik":"0001038977","reported_name":"WEISS MICHAEL S","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-04-29T16:24:45.000Z","date":"2022-01-01","kind":"grant","acquired":true,"shares":1102986,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 1,102,986 restricted shares pursuant to the Issuer's Long Term Incentive Plan on January 1, 2022."}],"balance_after":12335136,"source":{"system":"sec-edgar","filing":"0001104659-22-053619","document":"tm2213913-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1038977/000110465922053619/tm2213913-8_4seq1.xml","form_type":"4"}},{"id":2288036,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70396,"kind":"person","name":"LOBELL J JAY","position":1,"cik":"0001172659","reported_name":"LOBELL J JAY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2022-04-29T16:18:14.000Z","date":"2022-01-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of January 1, 2023, 2024 and 2025, subject to continued service."}],"balance_after":1236000,"source":{"system":"sec-edgar","filing":"0001104659-22-053578","document":"tm2213913-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172659/000110465922053578/tm2213913-3_4seq1.xml","form_type":"4"}},{"id":2752046,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":39449,"kind":"person","name":"Rowinsky Eric K","position":1,"cik":"0001318886","reported_name":"Rowinsky Eric K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2021-04-09T21:25:28.000Z","date":"2021-03-02","kind":"sale","acquired":false,"shares":10000,"price":4.45,"value":44500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"In connection with the vesting of 100,000 shares on January 1, 2021, a total of 30,000 shares were sold by the Reporting Person in order to satisfy the Reporting Person's tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on March 2, 2021, was $4.40 to $4.50.*"}],"balance_after":720000,"source":{"system":"sec-edgar","filing":"0001104659-21-048831","document":"tm219139d7_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465921048831/tm219139d7_4.xml","form_type":"4"}},{"id":2752045,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":39449,"kind":"person","name":"Rowinsky Eric K","position":1,"cik":"0001318886","reported_name":"Rowinsky Eric K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2021-04-09T21:25:28.000Z","date":"2021-02-19","kind":"sale","acquired":false,"shares":8000,"price":4.31,"value":34480.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"In connection with the vesting of 100,000 shares on January 1, 2021, a total of 30,000 shares were sold by the Reporting Person in order to satisfy the Reporting Person's tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on February 19, 2021, was $4.30 to $4.31.*"}],"balance_after":730000,"source":{"system":"sec-edgar","filing":"0001104659-21-048831","document":"tm219139d7_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465921048831/tm219139d7_4.xml","form_type":"4"}},{"id":2752044,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":39449,"kind":"person","name":"Rowinsky Eric K","position":1,"cik":"0001318886","reported_name":"Rowinsky Eric K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2021-04-09T21:25:28.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":6000,"price":4.2,"value":25200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"In connection with the vesting of 100,000 shares on January 1, 2021, a total of 30,000 shares were sold by the Reporting Person in order to satisfy the Reporting Person's tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on February 18, 2021, was $4.19 to $4.23.*"}],"balance_after":738000,"source":{"system":"sec-edgar","filing":"0001104659-21-048831","document":"tm219139d7_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465921048831/tm219139d7_4.xml","form_type":"4"}},{"id":2752043,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":39449,"kind":"person","name":"Rowinsky Eric K","position":1,"cik":"0001318886","reported_name":"Rowinsky Eric K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2021-04-09T21:25:28.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":2000,"price":3.86,"value":7720.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"In connection with the vesting of 100,000 shares on January 1, 2021, a total of 30,000 shares were sold by the Reporting Person in order to satisfy the Reporting Person's tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects an open market sale transaction effected by the Reporting Person through a sale order executed by a broker-dealer.*"}],"balance_after":744000,"source":{"system":"sec-edgar","filing":"0001104659-21-048831","document":"tm219139d7_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465921048831/tm219139d7_4.xml","form_type":"4"}},{"id":2752042,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":39449,"kind":"person","name":"Rowinsky Eric K","position":1,"cik":"0001318886","reported_name":"Rowinsky Eric K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2021-04-09T21:25:28.000Z","date":"2021-02-05","kind":"sale","acquired":false,"shares":4000,"price":3.8,"value":15200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"In connection with the vesting of 100,000 shares on January 1, 2021, a total of 30,000 shares were sold by the Reporting Person in order to satisfy the Reporting Person's tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on February 5, 2021, was $3.75 to $3.84.*"}],"balance_after":746000,"source":{"system":"sec-edgar","filing":"0001104659-21-048831","document":"tm219139d7_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465921048831/tm219139d7_4.xml","form_type":"4"}},{"id":2752041,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":39449,"kind":"person","name":"Rowinsky Eric K","position":1,"cik":"0001318886","reported_name":"Rowinsky Eric K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2021-04-09T21:25:28.000Z","date":"2021-01-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual grant of restricted shares of Issuer stock to members of the Issuer's Board of Directors. One-third of the shares will vest on each January 1, 2022, 2023 and 2024, subject to continued service."}],"balance_after":750000,"source":{"system":"sec-edgar","filing":"0001104659-21-048831","document":"tm219139d7_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465921048831/tm219139d7_4.xml","form_type":"4"}},{"id":2752375,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CEO & CHAIRMAN"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2021-04-09T21:24:52.000Z","date":"2021-01-01","kind":"grant","acquired":true,"shares":1030339,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The Reporting Person was granted 1,030,339 restricted shares pursuant to the Issuer's Long Term Incentive Plan on January 1, 2021."}],"balance_after":10407039,"source":{"system":"sec-edgar","filing":"0001104659-21-048830","document":"tm219139d6_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465921048830/tm219139d6_4.xml","form_type":"4"}},{"id":2752374,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CEO & CHAIRMAN"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2021-04-09T21:24:52.000Z","date":"2020-12-01","kind":"grant","acquired":true,"shares":1250,"price":2.34,"value":2925.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan (\"ESPP\") during the ESPP offering period."}],"balance_after":9376700,"source":{"system":"sec-edgar","filing":"0001104659-21-048830","document":"tm219139d6_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465921048830/tm219139d6_4.xml","form_type":"4"}},{"id":2752373,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":35267,"kind":"person","name":"ROSENWALD LINDSAY A MD","position":1,"cik":"0000941841","reported_name":"ROSENWALD LINDSAY A MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CEO & CHAIRMAN"}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2021-04-09T21:24:52.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":1602,"price":1.69,"value":2707.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan (\"ESPP\") during the ESPP offering period."}],"balance_after":9375450,"source":{"system":"sec-edgar","filing":"0001104659-21-048830","document":"tm219139d6_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/941841/000110465921048830/tm219139d6_4.xml","form_type":"4"}}],"next_cursor":"2021-04-09T21:24:52.000000Z,2752373"}